MTP Broad-Spectrum Antiviral
Viral inactivation across multiple virus families (Coronaviridae, Retroviridae, Flaviviridae, etc.)
Pre-clinicalActive
Key Facts
Indication
Viral inactivation across multiple virus families (Coronaviridae, Retroviridae, Flaviviridae, etc.)
Phase
Pre-clinical
Status
Active
Company
About VyraMed
VyraMed is an early-stage biotechnology company leveraging its proprietary MTP technology to develop a broad-spectrum antiviral agent. The company's core claim is the ability to achieve rapid, high-level viral inactivation against numerous virus families within one minute, as presented on its website. Currently operating as a private, pre-revenue entity, VyraMed's strategy seems focused on forging development partnerships to advance its technology toward clinical and commercial applications. Its ambitious value proposition targets a significant unmet need for fast-acting, non-specific antiviral interventions.
View full company profile